Impaired thymopoiesis occuring during the thymic involution of tumor-bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and A1

International Journal of Molecular Medicine

Volumn 23, Issue 1, 2009, Pages 89-98

  Carrio, Roberto ^a   Lopez, Diana M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

A1; Apoptosis; Bcl XL; Thymic involution; Tumor bearing mice

Indexed keywords

BCL2 RELATED PROTEIN A1; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; PROTEIN BCL XL; BCL2 PROTEIN, MOUSE; BCL2L1 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN BCL X; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER GROWTH; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; T LYMPHOCYTE SUBPOPULATION; THYMOCYTE; THYMUS ATROPHY; ADENOCARCINOMA; ANIMAL; ATROPHY; BAGG ALBINO MOUSE; CELL DEDIFFERENTIATION; CYTOLOGY; DOWN REGULATION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; T LYMPHOCYTE; THYMUS;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; ATROPHY; BCL-X PROTEIN; CELL DEDIFFERENTIATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES; THYMUS GLAND;

EID: 61749103179     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000105     Document Type: Article

References (72)

1. Miller JF: Effect of thymectomy in adult mice on immunological responsiveness. Nature 208: 1337-1338, 1965.
2. Haynes BF, Sempowski GD, Wells AF and Hale LP: The human thymus during aging. Immunol Res 22: 253-261, 2000.
3. Aspinall R: T cell development, ageing and Interleukin-7. Mech Ageing Dev 127: 572-578, 2006.
4. Scollay R, Wilson A, D'Amico A, et al: Developmental status and reconstitution potential of subpopulations of murine thymocytes. Immunol Rev 104: 81-120, 1988.
5. Godfrey DI, Kennedy J, Suda T and Zlotnik A: A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. J Immunol 150: 4244-4252, 1993.
6. Falk I and Eichmann K: Heterogeneity of the DN4 (CD44-CD25-) subset of CD4-CD8- double negative thymocytes; dependence on CD3 signaling. Immunol Lett 82: 123-130, 2002.
7. Fehling HJ and von Boehmer H: Early alpha beta T cell development in the thymus of normal and genetically altered mice. Curr Opin Immunol 9: 263-275, 1997.
8. Borowski C, Martin C, Gounari F, et al: On the brink of becoming a T cell. Curr Opin Immunol 14: 200-206, 2002.
9. Yokosuka T, Sakata-Sogawa K, Kobayashi W, et al: Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nat Immunol 6: 1253-1262, 2005.
10. Petrie HT, Livak F, Schatz DG, Strasser A, Crispe IN and Shortman K: Multiple rearrangements in T cell receptor alpha chain genes maximize the production of useful thymocytes. J Exp Med 178: 615-622, 1993.
11. Shortman K, Egerton M, Spangrude GJ and Scollay R: The generation and fate of thymocytes. Semin Immunol 2: 3-12, 1990.
12. Baumann S, Krueger A, Kirchhoff S and Krammer PH: Regulation of T cell apoptosis during the immune response. Curr Mol Med 2: 257-272, 2002.
13. Surh CD and Sprent J: T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372: 100-103, 1994.
14. Zhang N, Hartig H, Dzhagalov I, Draper D and He YW: The role of apoptosis in the development and function of T lymphocytes. Cell Res 15: 749-769, 2005.
15. Nunez G and Clarke MF: The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 4: 399-403, 1994.
16. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998.
17. Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
18. Boise LH, Gonzalez-Garcia M, Postema CE, et al: bcl-X, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
19. Kozopas KM, Yang T, Buchan HL, Zhou P and Craig RW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90: 3516-3520, 1993.
20. Lin EY, Orlofsky A, Berger MS and Prystowsky MB: Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 151: 1979-1988, 1993.
21. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
22. Chittenden T, Harrington EA, O'Connor R, et al: Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374: 733-736, 1995.
23. Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
24. Boyd JM, Gallo GJ, Elangovan B, et al: Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11: 1921-1928, 1995.
25. Wang K, Yin XM, Chao DT, Milliman CL and Korsmeyer SJ: BID: a novel BH3 domain-only death agonist. Genes Dev 10: 2859-2869, 1996.
26. Gibson L, Holmgreen SP, Huang DC, et al: bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13: 665-675, 1996.
27. Inohara N, Ding L, Chen S and Nunez G: Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 16: 1686-1694, 1997.
28. Inohara N, Ekhterae D, Garcia I, et al: Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL. J Biol Chem 273: 8705-8710, 1998.
29. Inohara N, Gourley TS, Carrio R, et al: Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem 273: 32479-32486, 1998.
30. Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673-682, 2001.
31. Gottschalk AR, Boise LH, Oltvai ZN, et al: The ability of Bcl-X(L) and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death Differ 3: 113-118, 1996.
32. Kim R: Unknotting the roles of Bcl-2 and Bcl-XL in cell death. Biochem Biophys Res Commun 333: 336-343, 2005.
33. Veis DJ, Sorenson CM, Shutter JR and Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75: 229-240, 1993.
34. Nakayama K, Nakayama K, Negishi I, et al: Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 261: 1584-1588, 1993.
35. Lopez-Hoyos M, Carrio R, Merino J and Merino R: Regulation of B cell apoptosis by Bcl-2 and Bcl-XL and its role in the development of autoimmune diseases (Review). Int J Mol Med 1: 475-483, 1998.
36. Grillot DA, Merino R and Nunez G: Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 182: 1973-1983, 1995.
37. Chao DT and Korsmeyer SJ: BCL-XL-regulated apoptosis in T cell development. Int Immunol 9: 1375-1384, 1997.
38. Tomayko MM, Punt JA, Bolcavage JM, Levy SL, Allman DM and Cancro MP: Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. Int Immunol 11: 1753-1761, 1999.
39. Verschelde C, Michonneau D, Trescol-Biemont MC, Berberich I, Schimpl A and Bonnefoy-Berard N: Overexpression of the antiapoptotic protein A1 promotes the survival of double positive thymocytes awaiting positive selection. Cell Death Differ 13: 1213-1221, 2006.
40. Aspinall R and Andrew D: Thymic involution in aging. J Clin Immunol 20: 250-256, 2000.
41. Linton PJ and Dorshkind K: Age-related changes in lymphocyte development and function. Nat Immunol 5: 133-139, 2004.
42. Taub DD and Longo DL: Insights into thymic aging and regeneration. Immunol Rev 205: 72-93, 2005.
43. Medina D and De Ome KB: Response of hyperplastic alveolar nodule outgrowth-line D1 to mammary tumor virus, noduleinducing virus, and prolonged hormonal stimulation acting singly and in combination. J Natl Cancer Inst 42: 303-310, 1969.
44. Fu YX, Altman N and Lopez DM: Thymic atrophy induced by murine mammary adenocarcinoma in vivo. In Vivo 3: 1-5, 1989.
45. Fu Y, Paul RD, Wang Y and Lopez DM: Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. J Immunol 143: 4300-4307, 1989.
46. Adkins B, Charyulu V, Sun QL, Lobo D and Lopez DM: Early block in maturation is associated with thymic involution in mammary tumor-bearing mice. J Immunol 164: 5635-5640, 2000.
47. Carrio R, Lopez-Hoyos M, Jimeno J, et al: A1 demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death. Am J Pathol 149: 2133-2142, 1996.
48. + T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment. J Immunol 172: 7315-7323, 2004.
49. Boise LH, Minn AJ, Noel PJ, et al: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3: 87-98, 1995.
50. Moore NC, Anderson G, Williams GT, Owen JJ and Jenkinson EJ: Developmental regulation of bcl-2 expression in the thymus. Immunology 81: 115-119, 1994.
51. Ciofani M and Zuniga-Pflucker JC: The thymus as an inductive site for T lymphopoiesis. Annu Rev Cell Dev Biol 23: 463-493, 2007.
52. Nowell CS, Farley AM and Blackburn CC: Thymus organo-genesis and development of the thymic stroma. Methods Mol Biol 380: 125-162, 2007.
53. Anderson G, Moore NC, Owen JJ and Jenkinson EJ: Cellular interactions in thymocyte development. Annu Rev Immunol 14: 73-99, 1996.
54. Giovannetti A, Pierdominici M, Di Iorio A, et al: Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr Pharm Des 14: 253-268, 2008.
55. Gonzalez-Garcia M, Perez-Ballestero R, Ding L, et al: bcl-XL is the major bcl-X mRNA form expressed during murine development and its product localizes to mitochondria. Development 120: 3033-3042, 1994.
56. Motoyama N, Wang F, Roth KA, et al: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506-1510, 1995.
57. Orlofsky A, Berger MS and Prystowsky MB: Novel expression pattern of a new member of the MIP-1 family of cytokine-like genes. Cell Regul 2: 403-412, 1991.
58. Lin EY, Orlofsky A, Wang HG, Reed JC and Prystowsky MB: A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation. Blood 87: 983-992, 1996.
59. Williams GT and Smith CA: Molecular regulation of apoptosis: genetic controls on cell death. Cell 74: 777-779, 1993.
60. Sedlak TW, Oltvai ZN, Yang E, et al: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92: 7834-7838, 1995.
61. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88: 386-401, 1996.
62. Simonian PL, Grillot DA, Merino R and Nunez G: Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL. J Biol Chem 271: 22764-22772, 1996.
63. Watson GA, Fu YX and Lopez DM: Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J Leukoc Biol 49: 126-138, 1991.
64. Fu YX, Watson G, Jimenez JJ, Wang Y and Lopez DM: Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 50: 227-234, 1990.
65. Lopez DM, Lopez-Cepero M, Watson GA, Ganju A, Sotomayor E and Fu YX: Modulation of the immune system by mammary tumor-derived factors. Cancer Invest 9: 643-653, 1991.
66. Calderon C, Huang ZH, Gage DA, Sotomayor EM and Lopez DM: Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. J Exp Med 180: 945-958, 1994.
67. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, Herbert LM, Grosso JF and Lopez DM: Up-regulation of matrix metallo-proteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 171: 4340-4351, 2003.
68. Piedrafita FJ and Pfahl M: Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 17: 6348-6358, 1997.
69. Lanning NJ and Carter-Su C: Recent advances in growth hormone signaling. Rev Endocr Metab Disord 7: 225-235, 2006.
70. Baumann S, Kyewski B, Bleckmann SC, et al: CREB function is required for normal thymic cellularity and post-irradiation recovery. Eur J Immunol 34: 1961-1971, 2004.
71. Megidish T, Xu JH and Xu CW: Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J Biol Chem 277: 8255-8259, 2002.
72. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.